These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21362317)

  • 1. Design of functional small interfering RNAs targeting amyotrophic lateral sclerosis-associated mutant alleles.
    Geng CM; Ding HL
    Chin Med J (Engl); 2011 Jan; 124(1):106-10. PubMed ID: 21362317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing allele.
    Geng CM; Ding HL
    Acta Pharmacol Sin; 2008 Feb; 29(2):211-6. PubMed ID: 18215350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
    Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
    Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing siRNA that distinguish between genes that differ by a single nucleotide.
    Schwarz DS; Ding H; Kennington L; Moore JT; Schelter J; Burchard J; Linsley PS; Aronin N; Xu Z; Zamore PD
    PLoS Genet; 2006 Sep; 2(9):e140. PubMed ID: 16965178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
    Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
    J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.
    Xia X; Zhou H; Huang Y; Xu Z
    Neurobiol Dis; 2006 Sep; 23(3):578-86. PubMed ID: 16857362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme.
    Yokota T; Miyagishi M; Hino T; Matsumura R; Tasinato A; Urushitani M; Rao RV; Takahashi R; Bredesen DE; Taira K; Mizusawa H
    Biochem Biophys Res Commun; 2004 Jan; 314(1):283-91. PubMed ID: 14715277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo application of an RNAi strategy for the selective suppression of a mutant allele.
    Kubodera T; Yamada H; Anzai M; Ohira S; Yokota S; Hirai Y; Mochizuki H; Shimada T; Mitani T; Mizusawa H; Yokota T
    Hum Gene Ther; 2011 Jan; 22(1):27-34. PubMed ID: 20649474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [RNAi and neurological disease].
    Yokota T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):973-5. PubMed ID: 16447777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells.
    Maxwell MM; Pasinelli P; Kazantsev AG; Brown RH
    Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3178-83. PubMed ID: 14981234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing strategies for therapy of SOD1-mediated ALS.
    van Zundert B; Brown RH
    Neurosci Lett; 2017 Jan; 636():32-39. PubMed ID: 27507699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression.
    Wang H; Ghosh A; Baigude H; Yang CS; Qiu L; Xia X; Zhou H; Rana TM; Xu Z
    J Biol Chem; 2008 Jun; 283(23):15845-52. PubMed ID: 18367449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi.
    Ohnishi Y; Tamura Y; Yoshida M; Tokunaga K; Hohjoh H
    PLoS One; 2008 May; 3(5):e2248. PubMed ID: 18493311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
    Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
    Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.
    Raoul C; Abbas-Terki T; Bensadoun JC; Guillot S; Haase G; Szulc J; Henderson CE; Aebischer P
    Nat Med; 2005 Apr; 11(4):423-8. PubMed ID: 15768028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gene therapy of ALS with short interfering RNA].
    Yokota T
    Brain Nerve; 2007 Oct; 59(10):1187-94. PubMed ID: 17969360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metal-deficient SOD1 in amyotrophic lateral sclerosis.
    Hilton JB; White AR; Crouch PJ
    J Mol Med (Berl); 2015 May; 93(5):481-7. PubMed ID: 25754173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short interfering RNA (siRNA) as a novel therapeutic.
    Pushparaj PN; Melendez AJ
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):504-10. PubMed ID: 16700886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress.
    Cookson MR; Menzies FM; Manning P; Eggett CJ; Figlewicz DA; McNeil CJ; Shaw PJ
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Jun; 3(2):75-85. PubMed ID: 12215229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superoxide dismutase 1 mutants related to amyotrophic lateral sclerosis induce endoplasmic stress in neuro2a cells.
    Oh YK; Shin KS; Yuan J; Kang SJ
    J Neurochem; 2008 Feb; 104(4):993-1005. PubMed ID: 18233996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.